RxSight, Inc. (RXST)

In July 2025, RxSight reported disappointing preliminary Q2 results, leading to a significant stock decline and analyst downgrades. In September 2025, RxSight outlined a strategic realignment at the Wells Fargo Healthcare Conference to address market slowdowns and competition. In November 2025, RxSight reported better-than-expected Q3 results, but the stock still declined. In December 2025, RxSight announced a CFO transition. In January 2026, RxSight announced preliminary Q4 and full-year 2025 results, exceeding revenue guidance, and appointed a new CFO, leading to a stock increase.

RxSight has indicated that typical seasonal trends for its products and services can be uncertain due to macroeconomic conditions and consumer sentiment. Historically, the company has anticipated overall quarterly sequential growth, with seasonality expected in the first and third quarters. The first quarter may experience softer sequential growth for capital equipment, while Light Adjustable Lens (LAL) procedures are expected to continue growing.

RxSight, Inc. is a medical technology company focused on cataract surgery outcomes through its adjustable intraocular lens (IOL) technology. The company operates in the Healthcare sector, specifically in the Medical Devices industry. Its core business involves the research, development, manufacture, and sale of its RxSight Light Adjustable Lens (LAL) system, the first commercially available IOL technology that allows doctors to customize a patient's visual acuity after cataract surgery. The company's major products include the RxSight Light Adjustable Lens (LAL/LAL+) and the RxSight Light Delivery Device (LDD). The LAL is an intraocular lens made of a photosensitive material that can be adjusted in shape and power using UV light. The LAL+ is a newer version designed to slightly extend the depth of focus. The LDD is an office-based light treatment device that delivers UV light to modify the LAL. The company operates on a "razor-and-blade" business model, with the LDD being the capital equipment and the LAL being the high-margin consumable.

RxSight, Inc. is headquartered in Aliso Viejo, California, United States. The company primarily operates in the United States, where it has achieved approximately 10% market share in the premium IOL market and its LDDs are adopted by over 25% of U.S. cataract surgeons. RxSight is also actively pursuing international expansion, with significant progress made in regulatory approvals and team building in major markets in Asia and Europe, anticipating continued progress in 2026.

RxSight has a strong brand reputation based on its innovative Light Adjustable Lens system, which allows post-operative customization of vision. However, financial underperformance and increased competition in the past year have challenged the company's reputation, leading to analyst downgrades. The company's commitment to innovation and strategic realignment efforts aim to reinforce its position in the ophthalmic medical device market.

RxSight, Inc. has a mixed ownership structure, with approximately 80.85% of the company's stock owned by institutional shareholders. Major institutional owners include BlackRock, Inc., Millennium Management Llc, and Vanguard Group Inc. Major individual/insider owners include RA Capital Management LP, Rxsight I LLC, and Ronald M. Md Kurtz (CEO).